Author: Daniel Ghinn

What HCPs say about Roche’s breast cancer drug

In June, NICE – the UK’s health spending policymaker – made a decision to recommend Kadcyla for use in breast cancer, following initial negative draft guidance, published in December 2016, which stated that the product was too expensive for routine funding on the NHS. Until that point, Kadcyla was only available to patients via the Cancer Drugs Fund (CDF), a source of funding with a fixed budget designed to provide fast access to new drugs. But, after Roche agreed to reduce the price of the drug to the NHS in England, NICE issued final guidance recommending it for use. Shortly afterwards it was announced...

Read More

Strategic Planning for Pharma in the Digital Age

Twenty years ago, the Internet promised to change everything. While doctors were starting to get online, set up email and websites, and join forums such as, pharmaceutical companies started to think about their own digital presence. Some companies set up their first website, a new channel for corporate communication. However, the traditional model of customer engagement – pharmaceutical representatives hoping to find a window in a doctor’s schedule for a few minutes of face-to-face time – was largely unchanged. A whole decade later, and some pharmaceutical companies were starting to ask questions about the digital behaviours of their...

Read More

How healthcare professionals engage NICE online

Three years ago, I told a story about healthcare professionals (HCPs) reaching out to NICE – the UK policymaker on NHS spending – and considered the role of influential online oncologists in shaping the organisation’s recommendation on cancer drug Xtandi. Since then, social media has continued to play a growing role in how UK healthcare professionals share ideas and engage with policymakers, as evidenced by new data showing the growth in mentions of NICE by HCPs using Twitter. A study of almost 12,000 Tweets by HCPs since the start of 2016, mentioning NICE’s main Twitter account, @NICEComms, or its website,...

Read More

Study of UK HCP conversation shows needs in Type 1 Diabetes care

A study of conversations about Type 1 Diabetes taking place on public social media among healthcare professionals in the UK shows that concern for patients is their number one priority. The study of 50,000 social media posts by more than 7,000 UK healthcare professionals was conducted using CREATION Pinpoint, a technology that tracks the online public conversations of more than 500,000 healthcare professionals worldwide. Speaking about the study findings, Junell Harrington, who led the research for CREATION, said that the study revealed how healthcare professionals were taking a lead in developing materials and initiatives to support patients: “There is...

Read More

Fifteen uses for Botox you never knew doctors talked about

Listening to healthcare professionals (HCPs) talking about medicines can provide a glimpse into their experiences with products, as well as their hopes or concerns about what they hear from each other. On social media, it is common to find physicians, pharmacists and other professionals discussing how they do or may treat patients; indeed, some specialists have said interacting with peers on social media has helped them to learn new approaches to treatment. Is it possible that the experiences of doctors, shared openly on public social media, could lead to clinical research and, eventually, the approval of new uses for...

Read More



The HCP insights eJournal for leaders in healthcare  Subscribe